Clinical Trial Detail

NCT ID NCT02204982
Title Study of IPI-145 in Combination With Rituximab vs Rituximab in Subjects With Previously Treated Follicular Lymphoma (DYNAMO + R)
Recruitment Terminated
Gender both
Phase Phase III
Variant Requirements No
Sponsors Infinity Pharmaceuticals, Inc.
Indications

non-Hodgkin lymphoma

Therapies

Duvelisib

Rituximab

Age Groups: adult

No variant requirements are available.